Cengild Medical Berhad (0243) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Cengild Medical Berhad MYR 0.24, price MYR 0.20, upside +20.0%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cengild Medical Berhad for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
53‑month range 0.1900 MYR – 0.5179 MYR · fair‑value band 0.1700 MYR – 0.3100 MYR · the 0.2000 MYR price screens below the 0.2400 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Cengild Medical Berhad in your weekly email
Every Wednesday you see whether Cengild Medical Berhad is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia.
Show more
Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiology; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy. It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; operating theatre, endoscopy, radiology and imaging services; accident and emergency care, and health screenings; and consultant services. Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.
Stock analysis
Cengild Medical Berhad (0243) currently trades at 0.2000 MYR, while our model-based Fair Value estimate is 0.2400 MYR, implying the stock looks roughly 16.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 0.2400 MYR per share, and 7 of the 16 models we run sit above the 0.2000 MYR price.
Bear case: the Asset-Based group reads lowest at 0.0900 MYR, and 9 of the 16 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.1700 MYR (bear) to 0.3100 MYR (bull), the price of 0.2000 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Cengild Medical Berhad reported revenue of 80.0M MYR in FY2025 versus 63.5M MYR in FY2021, a compound +6.0%/yr. Reported net income was 11.1M MYR in FY2025, compounding +2.5%/yr from FY2021.
Key figures
Market cap 167M MYR (≈ $40.9M) · P/E ratio 20.0 · P/S ratio 2.76 · EPS (TTM) 0.0100 MYR · Dividend yield 3.5% · Net margin 13.8% · Return on equity 9.0% · Return on assets (EBIT) 14.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 15% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 20%, 0243 screens richer than that median.
Fair Value models
Bear 0.1700 MYRFair Value 0.2400 MYRBull 0.3100 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (0.0030 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.3%
Dividend (yield on the price)3.5%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 19%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+20% · Above median
Profitability
Return on equity (TTM)9% · Above median
Return on assets3% · Below median
Net margin (TTM)13% · Top 25%
Operating margin (TTM)17% · Top 25%
Growth and dividend
Revenue growth−10% · Bottom 25%
Dividend yield (TTM)3.5% · Above median
Balance sheet
Debt / equity0.37× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cengild Medical Berhad Fair Value". https://www.fairvalue-calculator.com/stock/0243
Frequently asked questions
Is Cengild Medical Berhad (0243) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 0.2400 MYR versus a price of 0.2000 MYR, about +20% upside (undervalued).
What is the fair value of 0243?
Our model-based fair value for Cengild Medical Berhad is 0.2400 MYR (as of Sep 24, 2026), built from audited fundamentals. The current price: 0.2000 MYR.
What is the quality score of 0243?
Cengild Medical Berhad has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cengild Medical Berhad (0243)?
Our model-based price target is the fair value of 0.2400 MYR (as of Sep 24, 2026) from 16 valuation models. Cautious scenario 0.1700 MYR, optimistic scenario 0.3100 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Cengild Medical Berhad stock forecast for 2026?
Our models put fair value at 0.2400 MYR, about +20% upside versus a price of 0.2000 MYR (undervalued). Cautious scenario 0.1700 MYR, optimistic scenario 0.3100 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Cengild Medical Berhad (0243)?
Cengild Medical Berhad reported trailing-twelve-month revenue of about 73.2M MYR (latest available figure, as of Sep 24, 2026).
Does Cengild Medical Berhad pay a dividend?
Cengild Medical Berhad currently shows a dividend yield of about 3.50% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Cengild Medical Berhad (0243)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cengild Medical Berhad it is 0.2400 MYR per share (as of Sep 24, 2026), against a price of 0.2000 MYR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Cengild Medical Berhad stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0243 trades below its calculated fair value: price 0.2000 MYR, fair value 0.2400 MYR, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0243?
No. The price is what the market pays today (0.2000 MYR); the fair value is what the company's own numbers justify (0.2400 MYR). For Cengild Medical Berhad the two are 0.0400 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Cengild Medical Berhad worth?
The market values Cengild Medical Berhad at about 167M MYR (market capitalisation, as of Sep 24, 2026). Per share that is 0.2000 MYR; our models calculate a fair value of 0.2400 MYR per share.
What do the bullish and bearish scenarios say about 0243?
Our models span a range for Cengild Medical Berhad: cautious scenario 0.1700 MYR, base 0.2400 MYR, optimistic 0.3100 MYR per share (as of Sep 24, 2026, price 0.2000 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0243?
Cengild Medical Berhad trades at a price-to-earnings ratio of 20.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.2400 MYR is built from several models across several years. Other multiples: P/B 0.4, P/S 0.6, EV/EBITDA 5.0.
How solid is the balance sheet of Cengild Medical Berhad (0243)?
Balance-sheet figures for Cengild Medical Berhad (as of Sep 24, 2026): return on equity 9.0%, debt of 0.37 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 0243 from its 52-week high?
Cengild Medical Berhad trades at 0.2000 MYR, about 15% below its 52-week high of 0.2366 MYR and 5% above the low of 0.1900 MYR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2400 MYR is for.
Which stocks are comparable to Cengild Medical Berhad?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cengild Medical Berhad stock attractive at the current price?
The data as of Sep 24, 2026: price 0.2000 MYR, calculated fair value 0.2400 MYR (+20%), Quality Score 52/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0243 calculated?
We run Cengild Medical Berhad through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2400 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Cengild Medical Berhad currently trades 20 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cengild Medical Berhad (0243)?
The closing price on Sep 24, 2026 was 0.2000 MYR. Our model-based fair value is 0.2400 MYR, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cengild Medical Berhad right now?
Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (0.1700 MYR to 0.3100 MYR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Cengild Medical Berhad
How large is the market capitalisation of Cengild Medical Berhad (0243)?
The market capitalisation of Cengild Medical Berhad is 167M MYR (≈ $40.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cengild Medical Berhad (0243)?
The price-to-sales ratio of Cengild Medical Berhad is 2.76 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cengild Medical Berhad (0243)?
Earnings per share at Cengild Medical Berhad are 0.0100 MYR (price ÷ EPS = P/E 20.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cengild Medical Berhad (0243)?
The dividend yield of Cengild Medical Berhad is 3.5% (payout 70.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cengild Medical Berhad (0243)?
The net margin of Cengild Medical Berhad is 13.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cengild Medical Berhad (0243)?
The return on equity (ROE) of Cengild Medical Berhad is 9.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cengild Medical Berhad (0243)?
On an EBIT basis the return on assets of Cengild Medical Berhad is 14.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cengild Medical Berhad (0243)?
The operating margin of Cengild Medical Berhad is 16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cengild Medical Berhad (0243)?
Revenue at Cengild Medical Berhad is growing −9.7% versus a year earlier (3y avg +7.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cengild Medical Berhad (0243)?
Earnings per share at Cengild Medical Berhad are growing −14.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cengild Medical Berhad (0243) generate?
The free cash flow of Cengild Medical Berhad is −21.2M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cengild Medical Berhad (0243) carry?
The net debt of Cengild Medical Berhad is 31.0M MYR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cengild Medical Berhad in the live analysis
One click puts Cengild Medical Berhad on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
